 Ian Carroll
Concepts (79)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cerebrospinal Fluid Leak | 2 | 2024 | 47 | 1.630 |
Why?
| | Atrial Fibrillation | 3 | 2024 | 376 | 0.920 |
Why?
| | Blood Patch, Epidural | 1 | 2024 | 10 | 0.890 |
Why?
| | Patient Reported Outcome Measures | 2 | 2024 | 374 | 0.890 |
Why?
| | Intracranial Hypotension | 1 | 2024 | 40 | 0.840 |
Why?
| | Spine | 1 | 2022 | 160 | 0.710 |
Why?
| | Heart Failure | 4 | 2024 | 2133 | 0.570 |
Why?
| | Electrocardiography | 3 | 2024 | 611 | 0.360 |
Why?
| | Cardiomyopathy, Dilated | 2 | 2025 | 381 | 0.350 |
Why?
| | Propanolamines | 2 | 2021 | 97 | 0.330 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2024 | 72 | 0.230 |
Why?
| | Adrenergic beta-Antagonists | 3 | 2025 | 321 | 0.220 |
Why?
| | Receptors, Adrenergic, beta-1 | 2 | 2021 | 46 | 0.220 |
Why?
| | Multicenter Studies as Topic | 1 | 2024 | 286 | 0.210 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2023 | 82 | 0.200 |
Why?
| | Ventricular Fibrillation | 1 | 2023 | 57 | 0.200 |
Why?
| | Antifibrinolytic Agents | 1 | 2023 | 47 | 0.200 |
Why?
| | Ventricular Remodeling | 1 | 2025 | 255 | 0.200 |
Why?
| | ST Elevation Myocardial Infarction | 1 | 2023 | 52 | 0.200 |
Why?
| | Ventricular Function, Left | 1 | 2025 | 528 | 0.180 |
Why?
| | Blood Coagulation Disorders | 1 | 2023 | 167 | 0.180 |
Why?
| | Heart Rate | 1 | 2025 | 802 | 0.180 |
Why?
| | Psychometrics | 1 | 2024 | 696 | 0.170 |
Why?
| | Biological Products | 1 | 2023 | 205 | 0.170 |
Why?
| | Case-Control Studies | 2 | 2024 | 3378 | 0.160 |
Why?
| | Venous Thromboembolism | 1 | 2023 | 287 | 0.160 |
Why?
| | Phosphodiesterase 3 Inhibitors | 1 | 2019 | 14 | 0.160 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2024 | 1365 | 0.150 |
Why?
| | Middle Aged | 5 | 2025 | 31136 | 0.140 |
Why?
| | Data Interpretation, Statistical | 1 | 2018 | 337 | 0.130 |
Why?
| | Feeding and Eating Disorders | 1 | 2017 | 147 | 0.120 |
Why?
| | Models, Statistical | 1 | 2018 | 625 | 0.110 |
Why?
| | Humans | 12 | 2025 | 129625 | 0.110 |
Why?
| | Cohort Studies | 1 | 2024 | 5426 | 0.110 |
Why?
| | Male | 7 | 2025 | 63670 | 0.110 |
Why?
| | Receptors, Adrenergic | 2 | 2023 | 34 | 0.100 |
Why?
| | Treatment Outcome | 2 | 2025 | 10219 | 0.100 |
Why?
| | Female | 7 | 2025 | 68734 | 0.100 |
Why?
| | Aged | 4 | 2025 | 22061 | 0.100 |
Why?
| | Prospective Studies | 1 | 2024 | 7135 | 0.100 |
Why?
| | Magnetic Resonance Imaging | 1 | 2022 | 3394 | 0.090 |
Why?
| | Stroke Volume | 2 | 2025 | 592 | 0.080 |
Why?
| | Polymorphism, Genetic | 2 | 2023 | 637 | 0.070 |
Why?
| | Genotype | 2 | 2021 | 1833 | 0.060 |
Why?
| | Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels | 1 | 2025 | 33 | 0.060 |
Why?
| | Potassium Channels | 1 | 2025 | 149 | 0.060 |
Why?
| | Adult | 2 | 2024 | 35599 | 0.050 |
Why?
| | Cardiovascular Agents | 1 | 2025 | 157 | 0.050 |
Why?
| | Muscle Proteins | 1 | 2025 | 220 | 0.050 |
Why?
| | Thromboplastin | 1 | 2023 | 70 | 0.050 |
Why?
| | Norepinephrine | 1 | 2023 | 210 | 0.050 |
Why?
| | Heparin | 1 | 2023 | 254 | 0.050 |
Why?
| | Gene Regulatory Networks | 1 | 2023 | 281 | 0.050 |
Why?
| | Double-Blind Method | 1 | 2025 | 1875 | 0.040 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 3 | 1 | 2019 | 10 | 0.040 |
Why?
| | Metoprolol | 1 | 2019 | 39 | 0.040 |
Why?
| | Pharmacogenomic Variants | 1 | 2019 | 35 | 0.040 |
Why?
| | Hemorrhage | 1 | 2023 | 680 | 0.040 |
Why?
| | Pharmacogenomic Testing | 1 | 2019 | 61 | 0.040 |
Why?
| | Anticoagulants | 1 | 2023 | 637 | 0.040 |
Why?
| | Cyclic AMP | 1 | 2019 | 238 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2023 | 2128 | 0.040 |
Why?
| | Signal Transduction | 2 | 2023 | 4931 | 0.040 |
Why?
| | Pharmacogenetics | 1 | 2019 | 172 | 0.040 |
Why?
| | Myocardial Contraction | 1 | 2019 | 335 | 0.030 |
Why?
| | Mortality | 1 | 2019 | 307 | 0.030 |
Why?
| | Phenotype | 1 | 2025 | 3075 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1198 | 0.030 |
Why?
| | Precision Medicine | 1 | 2019 | 387 | 0.030 |
Why?
| | Myocytes, Cardiac | 1 | 2019 | 499 | 0.030 |
Why?
| | Computer Simulation | 1 | 2018 | 939 | 0.030 |
Why?
| | Inflammation | 1 | 2023 | 2750 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2021 | 4894 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2720 | 0.020 |
Why?
| | Time Factors | 1 | 2021 | 6555 | 0.020 |
Why?
| | Mice | 1 | 2023 | 16961 | 0.020 |
Why?
| | Animals | 1 | 2023 | 35391 | 0.010 |
Why?
| | Young Adult | 1 | 2017 | 12455 | 0.010 |
Why?
| | Adolescent | 1 | 2017 | 20412 | 0.010 |
Why?
|
|
Carroll's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|